The Basics
What is Indium 111 Ibritumomab Tiuxetan?
A radiolabeled monoclonal antibody used to find certain types of B-cell non-Hodgkin lymphoma.
Brand names for Indium 111 Ibritumomab Tiuxetan
Zevalin
How Indium 111 Ibritumomab Tiuxetan is classified
Radiopharmaceuticals, Indium Radioisotopes, Diagnostic Agents
Indium 111 Ibritumomab Tiuxetan During Pregnancy
Indium 111 Ibritumomab Tiuxetan pregnancy category
Category DNote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.
What we know about taking Indium 111 Ibritumomab Tiuxetan while pregnant
Based on its radioactivity, Y-90 Zevalin may cause fetal harm when administered to a pregnant woman. Immunoglobulins are known to cross the placenta. There are no adequate and well-controlled studies in pregnant women. Animal reproductive toxicology studies of Zevalin have not been conducted. Advise women of childbearing potential to use adequate contraception for a minimum of twelve months. Inform women who become pregnant while receiving Zevalin of the potential fetal risks.
Taking Indium 111 Ibritumomab Tiuxetan While Breastfeeding
What are recommendations for lactation if you're taking Indium 111 Ibritumomab Tiuxetan?
Information in this record refers to the use of indium 111 ibritumomab tiuxetan as a diagnostic agent. No information is available on the use of indium 111 ibritumomab tiuxetan during breastfeeding. Because of the long half-life of indium 111 and the potential for serious adverse reactions in nursing infants, the manufacturer recommends not administering the drug in women who wish to continue breastfeeding. If the drug is administered to a nursing mother, breastfeeding should be discontinued. If the drug is given, breastfeeding should be discontinued.
Maternal / infant drug levels
Information in this record refers to the use of indium 111 ibritumomab tiuxetan as a diagnostic agent. No information is available on the use of indium 111 ibritumomab tiuxetan during breastfeeding. Because of the long half-life of indium 111 and the potential for serious adverse reactions in nursing infants, the manufacturer recommends not administering the drug in women who wish to continue breastfeeding. If the drug is administered to a nursing mother, breastfeeding should be discontinued. If the drug is given, breastfeeding should be discontinued.
Possible effects of Indium 111 Ibritumomab Tiuxetan on milk supply
Relevant published information was not found as of the revision date.
Possible alternatives to Indium 111 Ibritumomab Tiuxetan
None listed
List of References
Lactation sources: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/1. Howe DB, Beardsley M, Bakhsh S. Appendix U. Model procedure for release of patients or human research subjects administered radioactive materials. In, NUREG-1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. Final report. U.S. Nuclear Regulatory Commission Office of Nuclear Material Safety and Safeguards. 2008;9, Rev. 2. http://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/
Disclaimer: This material is provided for educational purposes only and is not intended for medical advice, diagnosis, or treatment. Consult your healthcare provider with any questions.
